Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Sold by Janus Henderson Group PLC

Janus Henderson Group PLC lessened its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 83.4% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 360,191 shares of the biopharmaceutical company's stock after selling 1,815,450 shares during the period. Janus Henderson Group PLC owned about 0.30% of Catalyst Pharmaceuticals worth $7,160,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Pacer Advisors Inc. raised its holdings in Catalyst Pharmaceuticals by 130,918.8% in the 2nd quarter. Pacer Advisors Inc. now owns 2,967,575 shares of the biopharmaceutical company's stock worth $45,968,000 after purchasing an additional 2,965,310 shares during the period. Renaissance Technologies LLC raised its stake in shares of Catalyst Pharmaceuticals by 15.2% during the 2nd quarter. Renaissance Technologies LLC now owns 2,175,727 shares of the biopharmaceutical company's stock worth $33,702,000 after buying an additional 287,300 shares during the period. Integral Health Asset Management LLC acquired a new position in shares of Catalyst Pharmaceuticals during the 2nd quarter worth approximately $4,260,000. Dimensional Fund Advisors LP lifted its position in shares of Catalyst Pharmaceuticals by 9.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 3,000,756 shares of the biopharmaceutical company's stock valued at $46,479,000 after buying an additional 263,099 shares in the last quarter. Finally, Walleye Capital LLC acquired a new stake in Catalyst Pharmaceuticals in the 3rd quarter valued at $4,936,000. Institutional investors and hedge funds own 79.22% of the company's stock.

Catalyst Pharmaceuticals Stock Up 1.7 %

CPRX traded up $0.37 during trading on Tuesday, reaching $22.11. The company's stock had a trading volume of 744,070 shares, compared to its average volume of 1,175,021. The firm has a fifty day simple moving average of $21.52 and a two-hundred day simple moving average of $19.07. The company has a market cap of $2.64 billion, a price-to-earnings ratio of 18.74, a PEG ratio of 3.36 and a beta of 0.75. Catalyst Pharmaceuticals, Inc. has a 1 year low of $13.00 and a 1 year high of $24.27.

Analysts Set New Price Targets

Several equities analysts have issued reports on the stock. Truist Financial increased their price objective on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a "buy" rating in a report on Monday, November 11th. Stephens began coverage on shares of Catalyst Pharmaceuticals in a research note on Monday, November 18th. They issued an "overweight" rating and a $35.00 price target on the stock. Finally, HC Wainwright reiterated a "buy" rating and set a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Friday, November 8th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $31.14.

Insider Buying and Selling

In other news, insider Gary Ingenito sold 12,000 shares of the stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $22.72, for a total value of $272,640.00. Following the completion of the sale, the insider now owns 51,391 shares of the company's stock, valued at $1,167,603.52. This represents a 18.93 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Molly Harper sold 17,500 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $22.00, for a total transaction of $385,000.00. The disclosure for this sale can be found here. 11.00% of the stock is currently owned by company insiders.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.